Venous hypoxia has long been postulated as a potential cause of varicosity formation. This article aimed to review the development of this hypothesis, including evidence supporting and controversies surrounding it. Vein wall oxygenation is achieved by oxygen diffusing from luminal blood and vasa vasorum. The whole media of varicosities is oxygenated by vasa vasorum as compared to only the outer two-thirds of media of normal veins. There was no evidence that differences exist between oxygen content of blood from varicose and non-varicose veins, although the former demonstrated larger fluctuations with postural changes. Studies using cell culture and ex vivo explants demonstrated that hypoxia activated leucocytes and endothelium which released mediators regulating vein wall remodelling similar to those observed in varicosities. Venoactive drugs may improve venous oxygenation, and inhibit hypoxia activation of leucocytes and endothelium. The evidence for hypoxia as a causative factor in varicosities remains inconclusive, mainly due to heterogeneity and poor design of published in vivostudies. However, molecular studies have shown that hypoxia was able to cause inflammatory changes and vein wall remodelling similar to those observed in varicosities. Further studies are needed to improve our understanding of the role of hypoxia and help identify potential therapeutic targets.

1.
Lee AJ, Evans CJ, Allan PL, Ruckley CV, Fowkes FG: Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol 2003;56:171–179.
2.
International task force. The management of chronic venous disorders of the leg: an evidence-based report of an international task force. Epidemiology. Phlebology 1999;14(suppl 1):23.
3.
Nicolaides AN: Investigation of chronic venous insufficiency: a consensus statement (France, March 5–9, 1997). Circulation 2000;102:E126–E163.
4.
Raffetto JD, Khalil RA: Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 2008;23:85–98.
5.
Somers P, Knaapen M: The histopathology of varicose vein disease. Angiology 2006;57:546–555.
6.
Lim CS, Davies AH: Pathogenesis of primary varicose veins. Br J Surg 2009;96:1231–1242.
7.
Lim CS, Shalhoub J, Gohel MS, Shepherd AC, Davies AH: Matrix metalloproteinases in vascular disease – a potential therapeutic target? Curr Vasc Pharmacol 2010;8:75–85.
8.
Michiels C, Bouaziz N, Remacle J: Role of the endothelium and blood stasis in the development of varicose veins. Int Angiol 2002;21:18–25.
9.
Taccoen A, Lebard C, Borie H, Poullain JC, Zuccarelli F, Gerentes I, Stern S, Guichard M: Measurement of oxygen tension in normal and varicose vein walls (in French). J Mal Vasc 1996;21(suppl C):259–265.
10.
Kachlik D, Lametschwandtner A, Rejmontova J, Stingl J, Vanek I: Vasa vasorum of the human great saphenous vein. Surg Radiol Anat 2003;24:377–381.
11.
Lefebvre D, Lescalie F: Vascularization of the wall of the superficial veins. Anatomic study of the vasa vasorum (in French). J Mal Vasc 1996;21(suppl C):245–248.
12.
Kachlik D, Baca V, Stingl J, Sosna B, Lametschwandtner A, Minnich B, Setina M: Architectonic arrangement of the vasa vasorum of the human great saphenous vein. J Vasc Res 2007;44:157–166.
13.
Heistad DD, Armstrong ML, Amundsen S: Blood flow through vasa vasorum in arteries and veins: Effects of luminal PO2. Am J Physiol 1986;250:H434–H442.
14.
Bigel P, Taccoen A: Morphology and vascularization of the varicose internal saphenous vein. Comparison with the normal structure (in French). J Mal Vasc 1996;21(suppl C):249–252.
15.
Kachlik D, Stingl J, Sosna B, Straka Z, Lametschwandtner A, Minnich B, Fara P: Morphological features of vasa vasorum in pathologically changed human great saphenous vein and its tributaries. Vasa 2008;37:127–136.
16.
Michiels C, Arnould T, Remacle J: Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000;1497:1–10.
17.
Nicolaides AN: From symptoms to leg edema: Efficacy of Daflon 500 mg. Angiology 2003;54(suppl 1):S33–S44.
18.
Colm Malone P, Agutter PS: To what extent might deep venous thrombosis and chronic venous insufficiency share a common etiology? Int Angiol 2009;28:254–268.
19.
McEwan AJ, McArdle CS: Effect of hydroxyethylrutosides on blood oxygen levels and venous insufficiency symptoms in varicose veins. Br Med J 1971;2:138–141.
20.
deTakats G, Quint H, Tillotson BI, Crittenden PJ: The impairment of circulation in the varicose extremity. Arch Surg 1929;18:671.
21.
Reikerås O, Sorlie D: The significance of arteriovenous shunting for the development of varicose veins. Acta Chir Scand 1983;149:479–481.
22.
Scott HJ, Cheatle TR, McMullin GM, Coleridge Smith PD, Scurr JH: Reappraisal of the oxygenation of blood in varicose veins. Br J Surg 1990;77:934–936.
23.
Holling HE, Beecher HK, Linton RR: Study of the tendency to edema formation associated with incompetence of the valves of the communicating veins of the leg. Oxygen tension of the blood contained in varicose veins. J Clin Invest 1938;17:555–561.
24.
Murphy MA, Hands L: Is arteriovenous shunting involved in the development of varicosities? A study of the intraluminal pressure and oxygen content in varicose veins. Phlebology 2008;23:137–141.
25.
Schraibman IG: Blood oxygen saturation and dye-dilution studies in the investigation of the aetiology of varicose veins. Aust NZ J Surg 1966;36:136–144.
26.
Wali MA: Oxygenation of blood in varicose veins. Afr J Med Med Sci 2002;31:219–222.
27.
Blalock A: Oxygen content of blood in patients with varicose veins. Arch Surg 1929;19:298–305.
28.
Baron HC, Cassaro S: The role of arteriovenous shunts in the pathogenesis of varicose veins. J Vasc Surg 1986;4:124–128.
29.
Blumoff RL, Johnson G Jr: Saphenous vein PpO2 in patients with varicose veins. J Surg Res 1977;23:35–36.
30.
Jacob MP, Cazaubon M, Scemama A, Prie D, Blanchet F, Guillin MC, Michel JB: Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 2002;106:535–538.
31.
Takase S, Lerond L, Bergan JJ, Schmid-Schonbein GW: The inflammatory reaction during venous hypertension in the rat. Microcirculation 2000;7:41–52.
32.
Thomas PR, Nash GB, Dormandy JA: White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J (Clin Res Ed) 1988;296:1693–1695.
33.
Smith PD: Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999;36(suppl 1):24–36.
34.
Lengyel I, Acsady G: Histomorphological and pathobiochemical changes of varicose veins. A possible explanation of the development of varicosis. Acta Morphol Hung 1990;38:259–267.
35.
Niebes P: Vessel wall modification in venous pathology. Application to the study of phlebotonic drugs. Int Angiol 1996;15:88–92.
36.
Glowinski J, Glowinski S: Generation of reactive oxygen metabolites by the varicose vein wall. Eur J Vasc Endovasc Surg 2002;23:550–555.
37.
Flore R, Santoliquido A, Antonio DL, Pola E, Flex A, Pola R, Muzi MG, Farinon A, Rulli F, Gaetani E, Tondi P, Gerardino L, Gasbarrini A: Long saphenous vein stripping reduces local level of reactive oxygen metabolites in patients with varicose disease of the lower limbs. World J Surg 2003;27:473–475.
38.
Whiston RJ, Hallett MB, Davies EV, Harding KG, Lane IF: Inappropriate neutrophil activation in venous disease. Br J Surg 1994;81:695–698.
39.
Stvrtinova V, Ferencikova J: Lysosomal enzymes and superoxide production in polymorphonuclear leucocytes of patients with primary varicose veins. Cor Vasa 1992;34:255–264.
40.
Ciuffetti G, Mannarino E, Paltriccia R, Malagigi V, Sergi F, Paulisch P, Pasqualini L, Lupattelli G: Leucocyte activity in chronic venous insufficiency. Int Angiol 1994;13:312–316.
41.
Bougelet C, Roland IH, Ninane N, Arnould T, Remacle J, Michiels C: Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol 1998;345:89–95.
42.
Michiels C, Arnould T, Remacle J: Hypoxia-induced activation of endothelial cells as a possible cause of venous diseases: hypothesis. Angiology 1993;44:639–646.
43.
Arnould T, Michiels C, Alexandre I, Remacle J: Effect of hypoxia upon intracellular calcium concentration of human endothelial cells. J Cell Physiol 1992;152:215–221.
44.
Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J: Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem Pharmacol 1995;50:991–999.
45.
Michiels C, Arnould T, Knott I, Dieu M, Remacle J: Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol 1993;264:C866–C874.
46.
Michiels C, De Leener F, Arnould T, Dieu M, Remacle J: Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. Exp Cell Res 1994;213:43–54.
47.
Michiels C, Bouaziz N, Remacle J: Role of the endothelium and blood stasis in the appearance of varicose veins. Int Angiol 2002;21:1–8.
48.
Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G: Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006;107:2705–2712.
49.
Zhu XY, Daghini E, Chade AR, Lavi R, Napoli C, Lerman A, Lerman LO: Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. Life Sci 2008;83:801–809.
50.
Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, Li Y: Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1α and VEGF. J Cell Physiol 2009;218:66–74.
51.
Haider DG, Bucek RA, Giurgea AG, Maurer G, Glogar H, Minar E, Wolzt M, Mehrabi MR, Baghestanian M: PGE1 analog alprostadil induces VEGF and ENOS expression in endothelial cells. Am J Physiol Heart Circ Physiol 2005;289:H2066–H2072.
52.
Coulet F, Nadaud S, Agrapart M, Soubrier F: Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J Biol Chem 2003;278:46230–46240.
53.
Semenza GL: Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009;24:97–106.
54.
Cook-Johnson RJ, Demasi M, Cleland LG, Gamble JR, Saint DA, James MJ: Endothelial cell COX-2 expression and activity in hypoxia. Biochim Biophys Acta 2006;1761:1443–1449.
55.
Matagne D, Gilles R: Effect of O-(β-hydroxyethyl)-rutoside on the glucose metabolism of cultured human varicose saphenous veins. Arch Int Physiol Biochim 1977;85:133–138.
56.
Aunapuu M, Arend A: Histopathological changes and expression of adhesion molecules and laminin in varicose veins. Vasa 2005;34:170–175.
57.
Arnould T, Janssens D, Michiels C, Remacle J: Effect of aescine on hypoxia-induced activation of human endothelial cells. Eur J Pharmacol 1996;315:227–233.
58.
Arnould T, Michiels C, Janssens D, Delaive E, Remacle J: Hypoxia induces pmn adherence to umbilical vein endothelium. Cardiovasc Res 1995;30:1009–1016.
59.
Arnould T, Michiels C, Remacle J: Increased PMN adherence on endothelial cells after hypoxia: Involvement of PAF, CD18/CD11b, and ICAM-1. Am J Physiol 1993;264:C1102–C1110.
60.
Arnould T, Michiels C, Remacle J: Hypoxic human umbilical vein endothelial cells induce activation of adherent polymorphonuclear leukocytes. Blood 1994;83:3705–3716.
61.
Michiels C, Arnould T, Thibaut-Vercruyssen R, Bouaziz N, Janssens D, Remacle J: Perfused human saphenous veins for the study of the origin of varicose veins: role of the endothelium and of hypoxia. Int Angiol 1997;16:134–141.
62.
Michiels C, Remacle J, Bouaziz N: Endothelium and venotropic drugs in chronic venous insufficiency: a review. Phlebology 2002;17:145–150.
63.
Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D: Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2005;CD003229.
64.
Janssens D, Delaive E, Houbion A, Eliaers F, Remacle J, Michiels C: Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells. Br J Pharmacol 2000;130:1513–1524.
65.
Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, Van Landuyt H, Gillet-Terver MN, Guillot B, Levesque H, Mignot J, Pillion G, Fevrier B, Dubeaux D: Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77–85.
66.
Struckmann JR: Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res 1999;36(suppl 1):37–41.
67.
Gohel MS, Davies AH: Pharmacological agents in the treatment of venous disease: An update of the available evidence. Curr Vasc Pharmacol 2009;7:303–308.
68.
MacKay D: Hemorrhoids and varicose veins: a review of treatment options. Altern Med Rev 2001;6:126–140.
69.
Taccoen A, Belcaro G, Lebard C, Zuccarelli F: Pathogenesis and underlying mechanisms of varicose veins: review and future prospects. Sang Thrombose Vaisseaux 1997;9:354–363.
70.
Michiels C, Arnould T, Janssens D, Bajou K, Geron I, Remacle J: Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. Int Angiol 1996;15:124–130.
71.
Boyce JA, Mellor EA, Perkins B, Lim YC, Luscinskas FW: Human mast cell progenitors use α4-integrin, VCAM-1, and PSGL-1 E-selectin for adhesive interactions with human vascular endothelium under flow conditions. Blood 2002;99:2890–2896.
72.
Birukov KG: Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009;11:1651–1667.
73.
Koskinas KC, Chatzizisis YS, Baker AB, Edelman ER, Stone PH, Feldman CL: The role of low endothelial shear stress in the conversion of atherosclerotic lesions from stable to unstable plaque. Curr Opin Cardiol 2009;24:580–590.
74.
Lim CS, Gohel MS, Davies AH: Is there still a role for basic science research in venous disease? Phlebology 2008;23:147–148.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.